Xenetic Biosciences Inc Share Price Nasdaq
Equities
US9840152063
Biotechnology & Medical Research
Sales 2024 * | 2.13M 2.68M 213M | Sales 2025 * | 1.42M 1.78M 142M | Capitalization | 5.06M 6.35M 506M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.02M -400M | Net income 2025 * | -8M -10.05M -800M | EV / Sales 2024 * | 2.37 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-4.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 10/07/16 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 02/04/17 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 28/02/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 10/07/16 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 13/08/17 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |